Aura Biosciences Inc.

06/30/2022 | Press release | Distributed by Public on 06/30/2022 05:32

Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer - Form 8-K